Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LIPO | US
0
0%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.10
0.10
0.10
0.09
Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10 a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310 a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh Pennsylvania.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
116.6%1 month
944.4%3 months
678.1%6 months
442.0%-
-
2.35
0.05
0.04
-4.40
6.48
-
-4.74M
810.46K
810.46K
-
-697.93
-
27.90
-171.56
0.21
3.38
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.07
Range1M
0.14
Range3M
0.18
Rel. volume
1.32
Price X volume
5.76K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CARM | CARM | Biotechnology | 0.019 | 789.35K | 18900.00% | n/a | 1044.17% |
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.0075 | 752.47K | 0.00 | 0.00% | |
| Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 0.4693 | 707.23K | -32.57% | n/a | 0.00% |
| Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.0011 | 696.25K | 120.00% | n/a | -101.21% |
| Imc Mortgage Co | IMCC | Drug Manufacturers-Specialty & Generic | 0.296 | 672.88K | 8.11% | n/a | 222.75% |
| Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 0.5756 | 601.45K | -1.61% | n/a | 0.00% |
| IO Biotech Inc. Common Stock | IOBT | Biotechnology | 0.0085 | 559.99K | 3.66% | n/a | 2.23% |
| Arsanis Inc | ASNS | Biotechnology | 0.08 | 481.44K | 2.70% | n/a | 252.35% |
| Avenue Therapeutics Inc | ATXI | Drug Manufacturers-Specialty & Generic | 0.31 | 443.72K | -6.06% | 0.06 | 0.00% |
| Hepion Pharmaceuticals Inc | HEPA | Biotechnology | 0.061 | 353.75K | n/a | 4.33% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.40 | 0.53 | Cheaper |
| Ent. to Revenue | 6.48 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 678.06 | 72.80 | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 810.46K | 3.66B | Emerging |